A single-ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration of a MEK inhibitor, CH4987655 (RO4987655), in healthy volunteers: implications of clinical activity using a biological marker.

被引：0
|
作者：
Lee, Lucy
Niu, Huifeng
Rueger, Ruediger
Igawa, Yuriko
Deutsch, Jonathan
Ishii, Nobuya
Mu, Song
Sakamoto, Yuuichiro
Gimmi, Claude
Weissgerber, Georges
机构：
[1] Roche Pharmaceut, Nutley, NJ USA
[2] Roche Diagnost, Penzberg, Germany
[3] Chugai Pharmaceut, Tokyo, Japan
[4] Roche Pharmaceut, Basel, Switzerland
[5] Roche Clin Pharmacol Unit, Strasbourg, France
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3589
引用
收藏
页数：1
相关论文
共 6 条
  • [1] A single-ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration of a MEK inhibitor, CH4987655 (R04987655), in healthy volunteers: implications of clinical activity using a biological marker.
    Lee, Lucy
    Niu, Huifeng
    Rueger, Ruediger
    Igawa, Yuriko
    Deutsch, Jonathan
    Ishii, Nobuya
    Mu, Song
    Sakamoto, Yuuichiro
    Gimmi, Claude
    Weissgerber, Georges
    CANCER RESEARCH, 2009, 69
  • [2] Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
    Leijen, Suzanne
    Middleton, Mark R.
    Tresca, Patricia
    Kraeber-Bodere, Francoise
    Dieras, Veronique
    Scheulen, Max E.
    Gupta, Avinash
    Lopez-Valverde, Vanesa
    Xu, Zhi-Xin
    Rueger, Ruediger
    Tessier, Jean J. L.
    Shochat, Eliezer
    Blotner, Steve
    Naegelen, Valerie Meresse
    Schellens, Jan H. M.
    Eberhardt, Wilfried Ernst Erich
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4794 - 4805
  • [3] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
    Lee, Lucy
    Niu, Huifeng
    Rueger, Ruediger
    Igawa, Yuriko
    Deutsch, Jonathan
    Ishii, Nobuya
    Mu, Song
    Sakamoto, Yuuichiro
    Busse-Reid, Rachel
    Gimmi, Claude
    Goelzer, Petra
    De Schepper, Stefanie
    Yoshimura, Yashushi
    Barrett, Joanne
    Ishikawa, Yuji
    Weissgerber, Georges
    Peck, Richard
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7368 - 7374
  • [4] Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
    Moreno, Ofir
    Butler, Todd
    Zann, Vanessa
    Willson, Ashley
    Leung, Pui
    Connor, Alyson
    CLINICAL THERAPEUTICS, 2018, 40 (11) : 1855 - 1867
  • [5] Clinical pharmacokinetics and pharmacodynamics of ME-401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ, following single ascending dose administration to healthy volunteers
    Moreno, Ofir
    Imani, Robert
    Zann, Vanessa
    Leung, Pui
    CANCER RESEARCH, 2016, 76
  • [6] Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study
    Wang, Yuhao
    Yu, Chao
    Hu, Mengyue
    Wang, Lu
    Chen, Meixia
    Liu, Hanmo
    Wu, Nan
    Hou, Jie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
1